个人中心 - 老虎社区

lh2020

IP属地：重庆

帖子 · 2帖子 · 2
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- lh2020lh2020
  ·2021-03-18
  希望越来越好！
  昨夜今晨：美联储鸽声嘹亮！道指再创历史新高
  摘要联储放鸽美股收高，道指突破33000关口创新高；热门中概股周三收盘涨跌不一，拼多多跌超7%；美国联邦公开市场委员会3月17日会议声明全文；哔哩哔哩将于2021年3月18日至3月23日招股；隆力奇旗
  昨夜今晨：美联储鸽声嘹亮！道指再创历史新高
  2,768 评论
  点赞
  分享
  举报
- lh2020lh2020
  ·2021-03-16
  还有五家是什么公司呢？
  15 Fastest Growing Biotech Companies in the US
  In this article we talk about 15 fastest growing biotech companies in the US. You can skip our detai
  15 Fastest Growing Biotech Companies in the US
  2,200 评论
  点赞
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3558588066851736","uuid":"3558588066851736","gmtCreate":1596869797008,"gmtModify":1615882885426,"name":"lh2020","pinyin":"lh2020","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/85103cdd3049715f96811dfade6de995","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":7,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":1,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":2,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.01.02","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.09.18","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.13","exceedPercentage":"60.79%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"重庆","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":1,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":324427035,"gmtCreate":1616026725727,"gmtModify":1703496491724,"author":{"id":"3558588066851736","authorId":"3558588066851736","name":"lh2020","avatar":"https://static.tigerbbs.com/85103cdd3049715f96811dfade6de995","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3558588066851736","authorIdStr":"3558588066851736"},"themes":[],"htmlText":"希望越来越好！","listText":"希望越来越好！","text":"希望越来越好！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/324427035","repostId":"1119334973","repostType":2,"repost":{"id":"1119334973","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1616025406,"share":"https://ttm.financial/m/news/1119334973?lang=&edition=full","pubTime":"2021-03-18 07:56","market":"us","language":"zh","title":"昨夜今晨： 美联储鸽声嘹亮！道指再创历史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=1119334973","media":"老虎资讯综合","summary":"摘要联储放鸽美股收高，道指突破33000关口创新高；热门中概股周三收盘涨跌不一，拼多多跌超7%；美国联邦公开市场委员会3月17日会议声明全文；哔哩哔哩将于2021年3月18日至3月23日招股；隆力奇旗","content":"<p><b>摘要</b></p><blockquote>联储放鸽美股收高，道指突破33000关口创新高；</blockquote><blockquote>热门中概股周三收盘涨跌不一，<a href=\"https://laohu8.com/S/PDD\">拼多多</a>跌超7%；</blockquote><blockquote>美国联邦公开市场委员会3月17日会议声明全文；</blockquote><blockquote><a href=\"https://laohu8.com/S/BILI\">哔哩哔哩</a>将于2021年3月18日至3月23日招股；</blockquote><blockquote>隆力奇旗下聚好商城登陆纳斯达克，IPO首日收涨超24%。</blockquote><p>海外市场</p><p>1、联储放鸽美股收高 道指突破33000关口创新高</p><p>美股周三收高，道指史上首次站上33000关口，与标普指数均创历史新高。美联储维持利率不变，上调GDP与通胀预期。鲍威尔暗示2023年底前不会加息。美国国债收益率攀升，10年期美债收益率一度逼近1.69%。截至收盘，道琼斯指数涨0.58%，纳斯达克指数涨0.4%，标普500指数涨0.29%。其中，道指和标普500指数续创历史新高。</p><p>2、热门中概股周三收盘涨跌不一 <a href=\"https://laohu8.com/S/PDD\">拼多多</a>跌超7%</p><p>热门中概股周三收盘涨跌不一，区块链股集体上涨。拼多多跌超7%，该公司四季度财报显示营收265.5亿元，月活超7亿，创始人黄峥辞任董事长，由联合创始人、现任CEO陈磊接棒。</p><p>隆力奇旗下聚好商城今日登陆纳斯达克，股价收盘大涨超24%。</p><p>此外，途牛涨16%，<a href=\"https://laohu8.com/S/TME\">腾讯音乐</a>涨5%，<a href=\"https://laohu8.com/S/BIDU\">百度</a>涨3.8%，<a href=\"https://laohu8.com/S/BABA\">阿里巴巴</a>涨2.8%，<a href=\"https://laohu8.com/S/IQ\">爱奇艺</a>涨超2%。<a href=\"https://laohu8.com/S/LU\">陆金所</a>、YY欢聚时代、瑞幸粉单涨1%。<a href=\"https://laohu8.com/S/LIZI\">荔枝</a>跌超9%，拼多多跌超7%，<a href=\"https://laohu8.com/S/DOYU\">斗鱼</a>、<a href=\"https://laohu8.com/S/MOMO\">陌陌</a>跌超5%，<a href=\"https://laohu8.com/S/HUYA\">虎牙</a>、<a href=\"https://laohu8.com/S/NTES\">网易</a>有道跌超2%，<a href=\"https://laohu8.com/S/BILI\">哔哩哔哩</a>跌超1%。</p><p>3、欧股主要指数涨跌不一 <a href=\"https://laohu8.com/S/VUKE.UK\">英国富时100</a>指数跌0.6%</p><p>欧洲时间周三，欧股主要指数涨跌不一，截止收盘，英国伦敦股市《金融时报》100种股票平均价格指数17日报收于6762.67点，比前一交易日下跌40.94点，跌幅为0.60%。德国法兰克福股市DAX30指数报收于14596.61点，比前一交易日上涨39.03点，涨幅为0.27%。法国巴黎股市CAC40指数报收于6054.82点，比前一交易日下跌0.61点，跌幅为0.01%。</p><p>4、需求预期疲软+EIA原油库存增加 美油下跌四连阴</p><p>美国WTI 4月原油期货电子盘价格周三(3月17日)收盘下跌0.36美元，跌幅0.56%，报64.44美元/桶。油价周三连续第四日下滑，受欧洲需求疲软预期和美国原油库存增加拖累。</p><p>与此同时，ICE布伦特5月原油期货电子盘价格收盘下跌0.53美元，跌幅0.77%，报67.86美元/桶。</p><p>5、周三黄金期货收跌0.2% 美联储公布利率决定后反弹</p><p>黄金期货价格周三收跌。美国国债收益率继续攀升，令金价承压。但在美联储暗示在2023年底前不会加息后，金价略微回升。</p><p>6、议息结果前 美30年期债收益率创19个月高</p><p>联储局公布议息结果前，美国国库券孳息率全线上扬，其中，30年期美债息抽高6.7个基点，盘中暂时高位升至2.448厘，创下2019年8月以来新高。</p><p>10年期美债息上涨5.9个基点，现报1.676厘。20年期美债息报2.348厘，升5.9个基点；两年期美债收益率持稳于0.153厘；五年期美债息涨2.8个基点，报0.854厘。</p><p>国际宏观</p><p>1、美联储上调今年美国经济增速至6.5％，预计2023年底前不加息</p><p>美联储联邦公开市场委员会连续两天的议息会议结束。美联储点阵图显示，多数美联储联邦公开市场委员会官员预计2023年底前不会加息。具体来看，18名参与预测的官员一致预计将保持近零利率不变至少到2021年，14位官员预计保持近零利率不变至少至2022年，11位官员预计保持近零利率不变至少至2023年底。</p><p>2、美国联邦公开市场委员会3月17日会议声明全文</p><p>北京时间3月18日（周四）03：00，美国联邦公开市场委员会（FOMC）公布最新利率决议，将基准利率维持在0%-0.25%区间不变，将超额准备金率（IOER）维持在0.1%不变，将贴现利率维持在0.25%不变，符合市场的普遍预期。</p><p>3、巴西央行超预期加息75个基点 预计下次议息会议将再次加息</p><p>巴西央行周三宣布将基准利率上调75个基点至2.75%，市场预期为加息50个基点至2.5%。</p><p>巴西央行表示，利率决定是一致通过的，预计下次会议将再次加息75个基点。经济增长的不确定性仍高于往常，特别是今年的第一和第二季度。坚持经济改革是实现可持续复苏的关键。</p><p>4、欧盟公布重新开放计划 疫苗通行证给旅游业带来希望</p><p>欧盟执行部门提议引入数字证书，证明持有人或接种了疫苗，或已从感染中康复，或最近病毒检测呈阴性，因此不会构成重大健康风险。根据周三的公告，这种通行证旨在促进欧盟内部和对外的休闲旅行。/</p><p>5、英国首相：对中国进行“新冷战”是错误的，英国将与中国合作</p><p>当地时间 3 月 16 日，英国首相鲍里斯 · 约翰逊对议员发表讲话时称，英国希望与中国合作，包括建立更强大和积极的经济关系，以及在应对气候变化问题上的合作。</p><p>公司新闻</p><p>1、<a href=\"https://laohu8.com/NW/2120248138\" target=\"_blank\">华尔街大行首家 摩根士丹利将为高净值客户提供比特币基金</a></p><p>知情人士透露，摩根士丹利周三在一份内部备忘录中告诉其财务顾问，将推出三只基金，让投资者能够持有比特币。摩根士丹利成为首家为其富裕客户提供比特币基金渠道的美国大型银行。</p><p>2、<a href=\"https://laohu8.com/NW/2120136631\" target=\"_blank\">苹果即将发布新款iPad 进一步扩充得益于居家办公的产品线</a></p><p>知情人士称，<a href=\"https://laohu8.com/S/AAPL\">苹果</a>计划发布新款iPad Pro，配备更好的处理器和改进的相机。新型号的外观将与当前iPad Pro相似，同样有11英寸和12.9英寸屏幕的版本。</p><p>3、<a href=\"https://laohu8.com/NW/2120136116\" target=\"_blank\">哔哩哔哩将于2021年3月18日至3月23日招股</a></p><p>哔哩哔哩在港交所公告，将于2021年3月18日至3月23日招股，公开发售价将不超过988.00港元。预计将在2021年3月29日挂牌上市。</p><p>4、富士康计划生产电动汽车：旨在获得全球10％市场份额</p><p>日前，富士康宣布，将在美国或墨西哥建立首个电动汽车生产工厂，并希望未来获得全球电动车市场10%的市场份额。而对于最终电动汽车生产工厂的选址，刘扬伟表示，熟练劳动力和工程人才的可用性和成本将是关键性的决定因素之一，而最终结果将在7月1日之前揭晓。</p><p>今年2月，富士康与富士康与美国电动汽车初创企业Fisker签订协议，将为Fisker代工生产电动汽车产品，目标市场覆盖北美、欧洲、中国和印度，预计会在2023年第四季度正式量产，年产量将超过25万辆。</p><p>5、<a href=\"https://laohu8.com/NW/2120135955\" target=\"_blank\">隆力奇旗下聚好商城登陆纳斯达克，IPO首日收涨超24%</a></p><p>隆力奇旗下<a href=\"https://laohu8.com/S/JWEL\">聚好商城</a>周三在纳斯达克挂牌上市，该股周三高开43%，盘中涨幅一度达到近50%。截至收盘，该股大涨24.43%，报8.71美元，市值2.17亿美元。</p><p>此前该公司宣布，该公司以每股7美元的价格公开发售3，714，286股普通股。在扣除相应的发行费用前，预计募集资金总额为2600万美元。</p><p>6、<a href=\"https://laohu8.com/NW/2120136644\" target=\"_blank\">中通快递Q4营收82.571亿元，净利同比降44.3%</a></p><p>报告显示，中通快递第四季度营收为82.571亿元，比上年同期增长20.6%；净利润为12.916亿元，比上年同期的净利润下降44.3%。</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>昨夜今晨： 美联储鸽声嘹亮！道指再创历史新高</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n昨夜今晨： 美联储鸽声嘹亮！道指再创历史新高\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-03-18 07:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>摘要</b></p><blockquote>联储放鸽美股收高，道指突破33000关口创新高；</blockquote><blockquote>热门中概股周三收盘涨跌不一，<a href=\"https://laohu8.com/S/PDD\">拼多多</a>跌超7%；</blockquote><blockquote>美国联邦公开市场委员会3月17日会议声明全文；</blockquote><blockquote><a href=\"https://laohu8.com/S/BILI\">哔哩哔哩</a>将于2021年3月18日至3月23日招股；</blockquote><blockquote>隆力奇旗下聚好商城登陆纳斯达克，IPO首日收涨超24%。</blockquote><p>海外市场</p><p>1、联储放鸽美股收高 道指突破33000关口创新高</p><p>美股周三收高，道指史上首次站上33000关口，与标普指数均创历史新高。美联储维持利率不变，上调GDP与通胀预期。鲍威尔暗示2023年底前不会加息。美国国债收益率攀升，10年期美债收益率一度逼近1.69%。截至收盘，道琼斯指数涨0.58%，纳斯达克指数涨0.4%，标普500指数涨0.29%。其中，道指和标普500指数续创历史新高。</p><p>2、热门中概股周三收盘涨跌不一 <a href=\"https://laohu8.com/S/PDD\">拼多多</a>跌超7%</p><p>热门中概股周三收盘涨跌不一，区块链股集体上涨。拼多多跌超7%，该公司四季度财报显示营收265.5亿元，月活超7亿，创始人黄峥辞任董事长，由联合创始人、现任CEO陈磊接棒。</p><p>隆力奇旗下聚好商城今日登陆纳斯达克，股价收盘大涨超24%。</p><p>此外，途牛涨16%，<a href=\"https://laohu8.com/S/TME\">腾讯音乐</a>涨5%，<a href=\"https://laohu8.com/S/BIDU\">百度</a>涨3.8%，<a href=\"https://laohu8.com/S/BABA\">阿里巴巴</a>涨2.8%，<a href=\"https://laohu8.com/S/IQ\">爱奇艺</a>涨超2%。<a href=\"https://laohu8.com/S/LU\">陆金所</a>、YY欢聚时代、瑞幸粉单涨1%。<a href=\"https://laohu8.com/S/LIZI\">荔枝</a>跌超9%，拼多多跌超7%，<a href=\"https://laohu8.com/S/DOYU\">斗鱼</a>、<a href=\"https://laohu8.com/S/MOMO\">陌陌</a>跌超5%，<a href=\"https://laohu8.com/S/HUYA\">虎牙</a>、<a href=\"https://laohu8.com/S/NTES\">网易</a>有道跌超2%，<a href=\"https://laohu8.com/S/BILI\">哔哩哔哩</a>跌超1%。</p><p>3、欧股主要指数涨跌不一 <a href=\"https://laohu8.com/S/VUKE.UK\">英国富时100</a>指数跌0.6%</p><p>欧洲时间周三，欧股主要指数涨跌不一，截止收盘，英国伦敦股市《金融时报》100种股票平均价格指数17日报收于6762.67点，比前一交易日下跌40.94点，跌幅为0.60%。德国法兰克福股市DAX30指数报收于14596.61点，比前一交易日上涨39.03点，涨幅为0.27%。法国巴黎股市CAC40指数报收于6054.82点，比前一交易日下跌0.61点，跌幅为0.01%。</p><p>4、需求预期疲软+EIA原油库存增加 美油下跌四连阴</p><p>美国WTI 4月原油期货电子盘价格周三(3月17日)收盘下跌0.36美元，跌幅0.56%，报64.44美元/桶。油价周三连续第四日下滑，受欧洲需求疲软预期和美国原油库存增加拖累。</p><p>与此同时，ICE布伦特5月原油期货电子盘价格收盘下跌0.53美元，跌幅0.77%，报67.86美元/桶。</p><p>5、周三黄金期货收跌0.2% 美联储公布利率决定后反弹</p><p>黄金期货价格周三收跌。美国国债收益率继续攀升，令金价承压。但在美联储暗示在2023年底前不会加息后，金价略微回升。</p><p>6、议息结果前 美30年期债收益率创19个月高</p><p>联储局公布议息结果前，美国国库券孳息率全线上扬，其中，30年期美债息抽高6.7个基点，盘中暂时高位升至2.448厘，创下2019年8月以来新高。</p><p>10年期美债息上涨5.9个基点，现报1.676厘。20年期美债息报2.348厘，升5.9个基点；两年期美债收益率持稳于0.153厘；五年期美债息涨2.8个基点，报0.854厘。</p><p>国际宏观</p><p>1、美联储上调今年美国经济增速至6.5％，预计2023年底前不加息</p><p>美联储联邦公开市场委员会连续两天的议息会议结束。美联储点阵图显示，多数美联储联邦公开市场委员会官员预计2023年底前不会加息。具体来看，18名参与预测的官员一致预计将保持近零利率不变至少到2021年，14位官员预计保持近零利率不变至少至2022年，11位官员预计保持近零利率不变至少至2023年底。</p><p>2、美国联邦公开市场委员会3月17日会议声明全文</p><p>北京时间3月18日（周四）03：00，美国联邦公开市场委员会（FOMC）公布最新利率决议，将基准利率维持在0%-0.25%区间不变，将超额准备金率（IOER）维持在0.1%不变，将贴现利率维持在0.25%不变，符合市场的普遍预期。</p><p>3、巴西央行超预期加息75个基点 预计下次议息会议将再次加息</p><p>巴西央行周三宣布将基准利率上调75个基点至2.75%，市场预期为加息50个基点至2.5%。</p><p>巴西央行表示，利率决定是一致通过的，预计下次会议将再次加息75个基点。经济增长的不确定性仍高于往常，特别是今年的第一和第二季度。坚持经济改革是实现可持续复苏的关键。</p><p>4、欧盟公布重新开放计划 疫苗通行证给旅游业带来希望</p><p>欧盟执行部门提议引入数字证书，证明持有人或接种了疫苗，或已从感染中康复，或最近病毒检测呈阴性，因此不会构成重大健康风险。根据周三的公告，这种通行证旨在促进欧盟内部和对外的休闲旅行。/</p><p>5、英国首相：对中国进行“新冷战”是错误的，英国将与中国合作</p><p>当地时间 3 月 16 日，英国首相鲍里斯 · 约翰逊对议员发表讲话时称，英国希望与中国合作，包括建立更强大和积极的经济关系，以及在应对气候变化问题上的合作。</p><p>公司新闻</p><p>1、<a href=\"https://laohu8.com/NW/2120248138\" target=\"_blank\">华尔街大行首家 摩根士丹利将为高净值客户提供比特币基金</a></p><p>知情人士透露，摩根士丹利周三在一份内部备忘录中告诉其财务顾问，将推出三只基金，让投资者能够持有比特币。摩根士丹利成为首家为其富裕客户提供比特币基金渠道的美国大型银行。</p><p>2、<a href=\"https://laohu8.com/NW/2120136631\" target=\"_blank\">苹果即将发布新款iPad 进一步扩充得益于居家办公的产品线</a></p><p>知情人士称，<a href=\"https://laohu8.com/S/AAPL\">苹果</a>计划发布新款iPad Pro，配备更好的处理器和改进的相机。新型号的外观将与当前iPad Pro相似，同样有11英寸和12.9英寸屏幕的版本。</p><p>3、<a href=\"https://laohu8.com/NW/2120136116\" target=\"_blank\">哔哩哔哩将于2021年3月18日至3月23日招股</a></p><p>哔哩哔哩在港交所公告，将于2021年3月18日至3月23日招股，公开发售价将不超过988.00港元。预计将在2021年3月29日挂牌上市。</p><p>4、富士康计划生产电动汽车：旨在获得全球10％市场份额</p><p>日前，富士康宣布，将在美国或墨西哥建立首个电动汽车生产工厂，并希望未来获得全球电动车市场10%的市场份额。而对于最终电动汽车生产工厂的选址，刘扬伟表示，熟练劳动力和工程人才的可用性和成本将是关键性的决定因素之一，而最终结果将在7月1日之前揭晓。</p><p>今年2月，富士康与富士康与美国电动汽车初创企业Fisker签订协议，将为Fisker代工生产电动汽车产品，目标市场覆盖北美、欧洲、中国和印度，预计会在2023年第四季度正式量产，年产量将超过25万辆。</p><p>5、<a href=\"https://laohu8.com/NW/2120135955\" target=\"_blank\">隆力奇旗下聚好商城登陆纳斯达克，IPO首日收涨超24%</a></p><p>隆力奇旗下<a href=\"https://laohu8.com/S/JWEL\">聚好商城</a>周三在纳斯达克挂牌上市，该股周三高开43%，盘中涨幅一度达到近50%。截至收盘，该股大涨24.43%，报8.71美元，市值2.17亿美元。</p><p>此前该公司宣布，该公司以每股7美元的价格公开发售3，714，286股普通股。在扣除相应的发行费用前，预计募集资金总额为2600万美元。</p><p>6、<a href=\"https://laohu8.com/NW/2120136644\" target=\"_blank\">中通快递Q4营收82.571亿元，净利同比降44.3%</a></p><p>报告显示，中通快递第四季度营收为82.571亿元，比上年同期增长20.6%；净利润为12.916亿元，比上年同期的净利润下降44.3%。</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/b23574aac95526c9e5c62ebc8dd25130","relate_stocks":{},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1119334973","content_text":"摘要联储放鸽美股收高，道指突破33000关口创新高；热门中概股周三收盘涨跌不一，拼多多跌超7%；美国联邦公开市场委员会3月17日会议声明全文；哔哩哔哩将于2021年3月18日至3月23日招股；隆力奇旗下聚好商城登陆纳斯达克，IPO首日收涨超24%。海外市场1、联储放鸽美股收高 道指突破33000关口创新高美股周三收高，道指史上首次站上33000关口，与标普指数均创历史新高。美联储维持利率不变，上调GDP与通胀预期。鲍威尔暗示2023年底前不会加息。美国国债收益率攀升，10年期美债收益率一度逼近1.69%。截至收盘，道琼斯指数涨0.58%，纳斯达克指数涨0.4%，标普500指数涨0.29%。其中，道指和标普500指数续创历史新高。2、热门中概股周三收盘涨跌不一 拼多多跌超7%热门中概股周三收盘涨跌不一，区块链股集体上涨。拼多多跌超7%，该公司四季度财报显示营收265.5亿元，月活超7亿，创始人黄峥辞任董事长，由联合创始人、现任CEO陈磊接棒。隆力奇旗下聚好商城今日登陆纳斯达克，股价收盘大涨超24%。此外，途牛涨16%，腾讯音乐涨5%，百度涨3.8%，阿里巴巴涨2.8%，爱奇艺涨超2%。陆金所、YY欢聚时代、瑞幸粉单涨1%。荔枝跌超9%，拼多多跌超7%，斗鱼、陌陌跌超5%，虎牙、网易有道跌超2%，哔哩哔哩跌超1%。3、欧股主要指数涨跌不一 英国富时100指数跌0.6%欧洲时间周三，欧股主要指数涨跌不一，截止收盘，英国伦敦股市《金融时报》100种股票平均价格指数17日报收于6762.67点，比前一交易日下跌40.94点，跌幅为0.60%。德国法兰克福股市DAX30指数报收于14596.61点，比前一交易日上涨39.03点，涨幅为0.27%。法国巴黎股市CAC40指数报收于6054.82点，比前一交易日下跌0.61点，跌幅为0.01%。4、需求预期疲软+EIA原油库存增加 美油下跌四连阴美国WTI 4月原油期货电子盘价格周三(3月17日)收盘下跌0.36美元，跌幅0.56%，报64.44美元/桶。油价周三连续第四日下滑，受欧洲需求疲软预期和美国原油库存增加拖累。与此同时，ICE布伦特5月原油期货电子盘价格收盘下跌0.53美元，跌幅0.77%，报67.86美元/桶。5、周三黄金期货收跌0.2% 美联储公布利率决定后反弹黄金期货价格周三收跌。美国国债收益率继续攀升，令金价承压。但在美联储暗示在2023年底前不会加息后，金价略微回升。6、议息结果前 美30年期债收益率创19个月高联储局公布议息结果前，美国国库券孳息率全线上扬，其中，30年期美债息抽高6.7个基点，盘中暂时高位升至2.448厘，创下2019年8月以来新高。10年期美债息上涨5.9个基点，现报1.676厘。20年期美债息报2.348厘，升5.9个基点；两年期美债收益率持稳于0.153厘；五年期美债息涨2.8个基点，报0.854厘。国际宏观1、美联储上调今年美国经济增速至6.5％，预计2023年底前不加息美联储联邦公开市场委员会连续两天的议息会议结束。美联储点阵图显示，多数美联储联邦公开市场委员会官员预计2023年底前不会加息。具体来看，18名参与预测的官员一致预计将保持近零利率不变至少到2021年，14位官员预计保持近零利率不变至少至2022年，11位官员预计保持近零利率不变至少至2023年底。2、美国联邦公开市场委员会3月17日会议声明全文北京时间3月18日（周四）03：00，美国联邦公开市场委员会（FOMC）公布最新利率决议，将基准利率维持在0%-0.25%区间不变，将超额准备金率（IOER）维持在0.1%不变，将贴现利率维持在0.25%不变，符合市场的普遍预期。3、巴西央行超预期加息75个基点 预计下次议息会议将再次加息巴西央行周三宣布将基准利率上调75个基点至2.75%，市场预期为加息50个基点至2.5%。巴西央行表示，利率决定是一致通过的，预计下次会议将再次加息75个基点。经济增长的不确定性仍高于往常，特别是今年的第一和第二季度。坚持经济改革是实现可持续复苏的关键。4、欧盟公布重新开放计划 疫苗通行证给旅游业带来希望欧盟执行部门提议引入数字证书，证明持有人或接种了疫苗，或已从感染中康复，或最近病毒检测呈阴性，因此不会构成重大健康风险。根据周三的公告，这种通行证旨在促进欧盟内部和对外的休闲旅行。/5、英国首相：对中国进行“新冷战”是错误的，英国将与中国合作当地时间 3 月 16 日，英国首相鲍里斯 · 约翰逊对议员发表讲话时称，英国希望与中国合作，包括建立更强大和积极的经济关系，以及在应对气候变化问题上的合作。公司新闻1、华尔街大行首家 摩根士丹利将为高净值客户提供比特币基金知情人士透露，摩根士丹利周三在一份内部备忘录中告诉其财务顾问，将推出三只基金，让投资者能够持有比特币。摩根士丹利成为首家为其富裕客户提供比特币基金渠道的美国大型银行。2、苹果即将发布新款iPad 进一步扩充得益于居家办公的产品线知情人士称，苹果计划发布新款iPad Pro，配备更好的处理器和改进的相机。新型号的外观将与当前iPad Pro相似，同样有11英寸和12.9英寸屏幕的版本。3、哔哩哔哩将于2021年3月18日至3月23日招股哔哩哔哩在港交所公告，将于2021年3月18日至3月23日招股，公开发售价将不超过988.00港元。预计将在2021年3月29日挂牌上市。4、富士康计划生产电动汽车：旨在获得全球10％市场份额日前，富士康宣布，将在美国或墨西哥建立首个电动汽车生产工厂，并希望未来获得全球电动车市场10%的市场份额。而对于最终电动汽车生产工厂的选址，刘扬伟表示，熟练劳动力和工程人才的可用性和成本将是关键性的决定因素之一，而最终结果将在7月1日之前揭晓。今年2月，富士康与富士康与美国电动汽车初创企业Fisker签订协议，将为Fisker代工生产电动汽车产品，目标市场覆盖北美、欧洲、中国和印度，预计会在2023年第四季度正式量产，年产量将超过25万辆。5、隆力奇旗下聚好商城登陆纳斯达克，IPO首日收涨超24%隆力奇旗下聚好商城周三在纳斯达克挂牌上市，该股周三高开43%，盘中涨幅一度达到近50%。截至收盘，该股大涨24.43%，报8.71美元，市值2.17亿美元。此前该公司宣布，该公司以每股7美元的价格公开发售3，714，286股普通股。在扣除相应的发行费用前，预计募集资金总额为2600万美元。6、中通快递Q4营收82.571亿元，净利同比降44.3%报告显示，中通快递第四季度营收为82.571亿元，比上年同期增长20.6%；净利润为12.916亿元，比上年同期的净利润下降44.3%。","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":2768,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":325142577,"gmtCreate":1615881409799,"gmtModify":1703494379531,"author":{"id":"3558588066851736","authorId":"3558588066851736","name":"lh2020","avatar":"https://static.tigerbbs.com/85103cdd3049715f96811dfade6de995","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3558588066851736","authorIdStr":"3558588066851736"},"themes":[],"htmlText":"还有五家是什么公司呢？","listText":"还有五家是什么公司呢？","text":"还有五家是什么公司呢？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/325142577","repostId":"2114583555","repostType":2,"repost":{"id":"2114583555","kind":"news","pubTimestamp":1614435813,"share":"https://ttm.financial/m/news/2114583555?lang=&edition=full","pubTime":"2021-02-27 22:23","market":"us","language":"en","title":"15 Fastest Growing Biotech Companies in the US","url":"https://stock-news.laohu8.com/highlight/detail?id=2114583555","media":"Insider Monkey","summary":"In this article we talk about 15 fastest growing biotech companies in the US. You can skip our detai","content":"<html><body><p>In this article we talk about 15 fastest growing biotech companies in the US. You can skip our detailed analysis of the biotech industry and go to 5 Fastest Growing Biotech Companies in the US. </p>\n<p>Biotechnology is <a href=\"https://laohu8.com/S/AONE\">one</a> of the most consequential domains of the healthcare industry. Biotechnology uses biology and the functions of living organisms to make new treatments and technology for healthcare. Advances in biotechnology are stepping stones for human progress in key areas like genetics, DNA sequencing, recombinant gene techniques, applied immunology and diagnostics. Data shows that global biotechnology market is expected to cross $720 billion in value by 2025.</p>\n<h2>Why Are Investors Going Crazy For Biotech Stocks in 2021?</h2>\n<p>The coronavirus crisis was a huge catalyst for biotech companies, as the world struggled to find a cure for the disease and investors flocked to promising biotech companies working on COVID-19 vaccines. Famous biotech players like Moderna and Novavax Inc. soared to new highs as their vaccines started to show solid results. But relatively unknown biotech stocks like CytoDyn, <a href=\"https://laohu8.com/S/EQ\">Equillium Inc.</a> and Humanigen Inc. also received a lot of attention as the world suddenly realized that its apparent progress in healthcare is not enough, and that we still have major existential problems to resolve.</p>\n<h2>Small Companies, Big IPOs</h2>\n<p>Just after three years of inception, a biotech company named Sana Biotechnology recently went public, raising a whopping $58 million in what was reported to be the largest-ever IPO for a preclinical biotech. The Wall Street Journal reported before the IPO that the company, which makes technology for repairing and controlling genes in cells or replacing missing or damaged cells to treat several diseases, is valued at over $10 billion.</p>\n<p>Biotech companies burn a lot of cash and test investors’ patience before returning any money because they spend millions in research and development. But investors are ready to wait as they know the rewards are often big. After all, when Moderna went public in 2018, its $7 billion valuation looked insane and buying its stock felt risky. Today, the company is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the fastest growing biotech companies in the US, and expects about $11.7 billion in revenue in 2021 just from the government-purchase agreements for its COVID-19 vaccine. Moderna shares have gained 472% over the last 12 months.</p>\n<img height=\"500\" src=\"https://s.yimg.com/uu/api/res/1.2/uKd10s1NPFlQnYiEGx.BKw--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/insidermonkey.com/dd79dc45116b729606db7040e6e40f8b\" width=\"750\"/> NEstudio/Shutterstock.com \n<p>Another example is BioNTech, a once obscure German company that had to cut its IPO size after failing to satisfy investors. The company's shares soared to record highs after its vaccination (made in partnership with Pfizer) proved to be 90% effective. The stock is up 220% over the last 12 months.</p> It's becoming harder for investors to spot stocks with solid and real value. Even the smart money is finding it difficult to keep track of the swiftly changing world. The hedge fund industry’s reputation has been tarnished in the last decade during which its hedged returns couldn’t keep up with the unhedged returns of the market indices. On the other hand, Insider Monkey’s strategy of focusing on the top picks of over 800 hedge funds has helped it consistently beat the market over the last several years. We launched our monthly newsletter’s activist strategy nearly 4 years ago and this strategy’s picks returned 187.5% since then and beat the SPY by 111 percentage points. Our short strategy was also launched 4 years ago and its short recommendations gained a cumulative 8% (that’s a good thing because we are shorting them) since then. You can improve your returns by subscribing to our premium newsletters. \nOur subscription prices start at $6.99 per month and come with a 14-day full refund guarantee. \n<h2>Growth Potential for Biotech Stocks</h2>\n<p>Deloitte in a January 2021 report said that the life sciences industry, which includes biotechnology, will be “stronger than ever” in 2021 amid a rising demand, artificial intelligence, increasing partnerships and scientific breakthroughs.</p>\n<h2>Difference Between Biotech and Pharma</h2>\n<p>The biotech companies make use of living organisms for drug production but the pharmaceutical companies generally rely on chemicals and synthetic processes in order to manufacture medicines. Biotechnology brought a significantly new drug development strategy that did not fully amalgamate into the chemical-based approach of the established pharmaceutical companies.</p>\n<p>In order to determine the fastest growing biotech companies in the US, we have compared the revenue of 2018 to the revenue of 2019 for some of the best and innovative biotech companies.</p>\n<p>Let's now take a look at our list of the 15 fastest growing biotech companies in the US.</p>\n<h3><strong><em>15. </em>Sorrento Therapeutics, Inc. (NASDAQ: SRNE)</strong></h3>\n<p><strong><em>Headquarters: </em></strong><strong><em>San Diego, CA</em></strong></p>\n<p><strong><em>No. of employees: 310</em></strong></p>\n<p><strong><em>Revenue (2018): $21.2 million</em></strong></p>\n<p><strong><em>Revenue (2019): $31.43 million</em></strong></p>\n<p>Founded in 2006, Sorrento Therapeutics, Inc. is a clinical-stage biotechnology company that makes novel immunotherapies for inflammatory, autoimmune, cancer, metabolic, and neurodegenerative maladies.  Its product portfolio incorporates biosimilars, cellular therapy, immuno-oncology antibodies, and antibody-drug conjugates (ADCs). The company's primary segment is related to Immune-Oncology therapeutic area while the Scilex segment is primarily concerned with the non-opioid pain management system.  Sorrento has established one of the most diverse antibody  libraries that boasts a myriad of superior quality, fully human antibodies.</p>\n<p>Regarding the COVID-19 pandemic, Sorrento is working on new antibody therapeutics. To develop an intramuscular injection that can neutralize Covid-19 and its variant strains, the company got a whopping $34 million contract from Defense Advanced Research Projects Agency (DARPA) in November.</p>\n<p>The company has a slew of diagnostic tests and preventative/ treatment antibody treatments in its pipeline. Sorrento has already received clearance from FDA to proceed with Phase 1 Clinical Trials for STI-2020.</p>\n<h3><strong>14. <a href=\"https://laohu8.com/S/EDIT\">Editas Medicine, Inc.</a> (NASDAQ: EDIT)</strong></h3>\n<p><strong><em>Headquarters: Cambridge, Massachusetts</em></strong></p>\n<p><strong><em>No. of employees: </em></strong><strong><em>208</em></strong></p>\n<p><strong><em>Revenue (2018): $32 million</em></strong></p>\n<p><strong><em>Revenue (2019): $20.5 million</em></strong></p>\n<p>Founded in 2013, Editas Medicine, Inc. is a genome editing company that makes therapies based on CRISPR genome editing systems. The CRISPR technology entails CRISPR/Cas9, CRISPR/Cas12a, and the engineered hybrid of these two systems to target the diseases at the genetic level. It is also involved in research collaboration with <a href=\"https://laohu8.com/S/JUNO\">Juno Therapeutics</a>, Inc.</p>\n<h3><strong>13. Intellia Therapeutics, Inc. (NASDAQ: NTLA)</strong></h3>\n<p><strong><em>Headquarters: Cambridge, Massachusetts</em></strong></p>\n<p><strong><em>No. of employees: </em></strong><strong><em>270</em></strong></p>\n<p><strong><em>Revenue (2018): $30.4 million</em></strong></p>\n<p><strong><em>Revenue (2019): $43.1 million</em></strong></p>\n<p>Founded in 2014, Intellia Therapeutics is a biotechnology company that is a pioneer in the development of CRISPR/Cas9 genome editing.  The company uses Lipid Nanoparticle (LNP) for the delivery of the CRISPR/Cas9 complex to the liver. It has a license agreement and strategic collaboration with Novartis on developing novel ex vivo CRISPR/Cas9-based therapies. The company's NTLA-2002 is a candidate for the treatment of Hereditary Angioedema (HAE) while NTLA-5001 is their initial ex vivo development candidate which targets to treat Acute Myeloid Leukemia (AML).</p>\n<p>The new division of the company, eXtellia Therapeutics, is engaged in the application of CRISPR/Cas9 genome editing in the domain of immuno-oncology and autoimmune/inflammatory diseases.</p>\n<h3><strong>12. <a href=\"https://laohu8.com/S/BPMC\">Blueprint Medicines Corporation</a> (NASDAQ: BPMC)</strong></h3>\n<p><strong><em>Headquarters: Cambridge, Massachusetts</em></strong></p>\n<p><strong><em>No. of employees: </em></strong><strong><em>420</em></strong></p>\n<p><strong><em>Revenue (2018): $44.5 million</em></strong></p>\n<p><strong><em>Revenue (2019): $66.5 million</em></strong></p>\n<p>Founded in 2008, Blueprint Medicines Corporation is a biopharmaceutical company that focuses on the diseases triggered by kinase activation. In January 2020 BLU-285(Ayvakit) was approved by the FDA as a treatment of metastatic GIST harboring a PDGFRA exon 18 mutation as well as PDGFRA D842V mutations. Its drug BLU-667(Gavreto) won the FDA approval for the treatment of adults with metastatic RET fusion-positive non-small-cell lung cancer (“NSCLC”). The company's pipeline of primary drug candidates includes BLU-554(Fisogatinib), which is for patients with advanced Hepatocellular Carcinoma (HCC), and BLU-945, which is designed to target EGFR tumors.</p>\n<h3><strong>11. <a href=\"https://laohu8.com/S/XLRN\">Acceleron Pharma Inc.</a> (NASDAQ: XLRN)</strong></h3>\n<p><strong><em>Headquarters: Cambridge, Massachusetts.</em></strong></p>\n<p><strong><em>No. of employees: </em></strong><strong><em>237</em></strong></p>\n<p><strong><em>Revenue (2018): $14 million</em></strong></p>\n<p><strong><em>Revenue (2019): $74 million</em></strong></p>\n<p>Founded in 2003, Acceleron Pharma Inc. is a biopharmaceutical company that is involved in developing protein therapies to neutralize certain types of rare diseases and cancer.  The company has prioritized and focused its research and development projects around three main therapeutic fields: neuromuscular, pulmonary, and hematology.</p>\n<p>On April 3, 2020, the FDA approved the company's luspatercept-aamt for anemia in adults with MDS. Its candidates which are undergoing clinical trials include ACE-083, designed for the treatment of focal muscle disorders; Sotatercept, designed to treat pulmonary arterial hypertension; and <em>ACE</em>-<em>1334</em> for the treatment of Systemic Sclerosis.</p>\n<p>The company has partnerships with biotech giants like Bristol-Myers Squibb, Alkermes and Shire.</p>\n<h3><strong>10. Fate Therapeutics, Inc. (NASDAQ: FATE)</strong></h3>\n<p><strong><em>Headquarters: San Diego, California</em></strong></p>\n<p><strong><em>No. of employees: 178</em></strong></p>\n<p><strong><em>Revenue (2018): 4.740 million</em></strong></p>\n<p><strong><em>Revenue (2019): 10.7 million</em></strong></p>\n<p>Ranking 10th on our list of 15 fastest growing biotech companies in the US is Fate. Founded in 2007, Fate Therapeutics, Inc. is a biopharmaceutical company that is engaged in the development of programmed cellular immunotherapies for immune disorder and cancer.  Its pipeline of products entails immuno-regulation candidates and immuno-oncology candidates. ProHema is its lead candidate drug which utilizes the blood of the umbilical cord to treat hematologic malignancies. The company programs immune cells, such as T cells, Natural Killer (NK) cells, and CD34+ cells by utilizing its cell programming approach. Its under-development programs include FT500, FT516, and FT-ONO2 to treat advanced solid tumors; FT516 to treat acute myeloid leukemia (AML) and B-cell lymphoma; FT538 for the treatment of AML and multiple myeloma; FT576 to treat multiple myeloma; FT596 to treat B-cell lymphoma and CLL; FT819 to treat B-cell malignancies, and FT-ONO1 to treat hematologic malignancies.</p>\n<h3><strong>9. Mirati Therapeutics, Inc. (NASDAQ: MRTX)</strong></h3>\n<p><strong><em>Headquarters: San Diego, California</em></strong></p>\n<p><strong><em>No. of employees: 111</em></strong></p>\n<p><strong><em>Revenue (2018): $13 million</em></strong></p>\n<p><strong><em>Revenue (2019): $3.3 million</em></strong></p>\n<p>Founded in 1995, Mirati Therapeutics, Inc. ranks 9th on our list of 15 fastest growing biotech companies in the US. It has a pipeline of oncology products for treating particular genetic and epigenetic drivers of cancer in selected subsets of patients having limited treatment options.  The company's clinical programs include two major product candidates: Sitravatinib, a multi-kinase inhibitor, and MRTX849, a Kirsten Rat Sarcoma (KRAS) G12C inhibitor. MRTX849 is designed for treating non-small cell lung (NSCL), pancreatic, colorectal, and other cancers while Sitravatinib is designed for treating NSCL cancer, and for inhibiting receptor tyrosine kinases (RTKs).</p>\n<h3><strong>8. <a href=\"https://laohu8.com/S/RARE\">Ultragenyx Pharmaceutical Inc</a>. (NASDAQ: RARE)</strong></h3>\n<p><strong><em>Headquarters: Novato, California.</em></strong></p>\n<p><strong><em>No. of employees: 740</em></strong></p>\n<p><strong><em>Revenue (2018): $51.5 million</em></strong></p>\n<p><strong><em>Revenue (2019): $104 million</em></strong></p>\n<p>Founded in 2010, Ultragenyx Pharmaceutical Inc., is one of the 15 fastest growing biotech companies in the US. It works on novel drugs for neutralizing rare and ultra-rare diseases concerned with genetics. The candidate products of Ultragenyx are categorized into three types: gene therapy, biologics, and small molecule products. The portfolio of the company's medicine includes Crysvita (KRN23), Mepsevii (UX003), and Triheptatonin (UX007). Crysvita is for treating the X-linked hypophosphatemia (XLH) in adults and pediatric patients while Mepsevii is for treating the Mucopolysaccharidosis VII indicated in pediatric and adult patients. The US market accounts for around 85% of the company's revenue.</p>\n<p>The company's clinical-stage pipeline consists of two candidates: DTX 301 which is developed for the treatment of individuals with ornithine transcarbamylase (OTC) deficiency and DTX 401 for the treatment of patients with Glycogen Storage Disease Type 1a (GSDIa).</p>\n<h3><strong>7. <a href=\"https://laohu8.com/S/ABCL\">AbCellera Biologics</a> Inc. (NASDAQ: ABCL)</strong></h3>\n<p><strong><em>Headquarters: Vancouver, Canada.</em></strong></p>\n<p><strong><em>No. of employees: </em></strong><strong><em> 174</em></strong></p>\n<p><strong><em>Revenue (2018): $8.8 million</em></strong></p>\n<p><strong><em>Revenue (2019): $11.6 million</em></strong></p>\n<p>Founded in 2012, AbCellera Biologics Inc. is a biotechnology company that focuses on developing antibodies to prevent and treat highly infectious diseases.  Its platform entails and integrates technology tools from single- microfluidics, cell analysis, engineering, high-throughput genomics, data science, and machine learning.  The company is also involved in developing next-generation transgenic mice for the detection of therapeutic antibody candidates.</p>\n<p>The company's subsidiaries include AbCellera Properties Columbia Inc., AbCellera Properties Inc., Lineage Biosciences Inc., Channel Biologics Pty Ltd., AbCellera US Holdings Inc. and Trianni, Inc.</p>\n<p>Bamlanivimab (LY-CoV555), the drug discovered by AbCellera and developed with Eli Lily &amp; Co., has received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) to be used in combination with <em>Etesevimab (LY</em>-CoV016) for the treatment of COVID-19.</p>\n<h3><strong>6. Zai Lab Limited (NASDAQ: ZLAB)</strong></h3>\n<p><strong><em>Headquarters: Shanghai, China.</em></strong></p>\n<p><strong><em>No. of employees: 859</em></strong></p>\n<p><strong><em>Revenue (2018): $129,000</em></strong></p>\n<p><strong><em>Revenue (2019): $12.9 million</em></strong></p>\n<p>Ranking 6th on our list of 15 fastest growing biotech companies in the US is ZLAB. Zai Lab Limited is a biopharmaceutical company that focuses on developing and commercializing drugs related to the fields of oncology, autoimmune, and infectious diseases. The flagship products of the company include Niraparib for the treatment of multiple solid tumors, and Optune, a cancer therapy for treating glioblastoma multiforme. The company's pipeline of proprietary drug candidates includes discovery-stage to late-stage clinical programs. It includes Fugan (ZL-3101), ZL-2103, ZL-2302, ZL-1101, and several others.</p>\n<p><strong>Click to continue reading and see 5 Fastest Growing Biotech Companies in the US.</strong></p>\n<p>Suggested articles:</p>\n<ul>\n<li><strong>15 Fastest Growing Channels On YouTube in 2020</strong></li>\n<li><strong>15 Biggest Outsourcing Companies In The World</strong></li>\n<li><strong>10 Best Long-Term Dividend Stocks to Buy and Hold</strong></li>\n</ul>\n<p>Disclosure: None. <strong>1</strong><strong>5 Fastest Growing Biotech Companies in the US</strong> is originally published on Insider Monkey.</p></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>15 Fastest Growing Biotech Companies in the US</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n15 Fastest Growing Biotech Companies in the US\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-02-27 22:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/15-fastest-growing-biotech-companies-142333559.html><strong>Insider Monkey</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In this article we talk about 15 fastest growing biotech companies in the US. You can skip our detailed analysis of the biotech industry and go to 5 Fastest Growing Biotech Companies in the US. \n...</p>\n\n<a href=\"https://finance.yahoo.com/news/15-fastest-growing-biotech-companies-142333559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/Mpe7slxsBb8vbkdn6p6ziQ--~B/aD01MDA7dz03NTA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/3MQV1HsGZxRZPOpQ8npGCQ--~B/aD01MDA7dz03NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/dd79dc45116b729606db7040e6e40f8b","relate_stocks":{"MRNA":"Moderna, Inc.","TERN":"Terns Pharmaceuticals, Inc.","CVAC":"CureVac B.V.","BPMC":"Blueprint Medicines Corporation","SRNE":"索伦托医疗","XLRN":"Acceleron Pharma Inc.","ZLAB":"再鼎医药","MRTX":"Mirati Therapeutics Inc.","SGEN":"Seagen","ABCL":"AbCellera Biologics","NTLA":"Intellia Therapeutics Inc","RARE":"Ultragenyx Pharmaceutical Inc","FATE":"Fate Therapeutics Inc","EDIT":"Editas Medicine, Inc.","BNTX":"BioNTech SE","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://finance.yahoo.com/news/15-fastest-growing-biotech-companies-142333559.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2114583555","content_text":"In this article we talk about 15 fastest growing biotech companies in the US. You can skip our detailed analysis of the biotech industry and go to 5 Fastest Growing Biotech Companies in the US. \nBiotechnology is one of the most consequential domains of the healthcare industry. Biotechnology uses biology and the functions of living organisms to make new treatments and technology for healthcare. Advances in biotechnology are stepping stones for human progress in key areas like genetics, DNA sequencing, recombinant gene techniques, applied immunology and diagnostics. Data shows that global biotechnology market is expected to cross $720 billion in value by 2025.\nWhy Are Investors Going Crazy For Biotech Stocks in 2021?\nThe coronavirus crisis was a huge catalyst for biotech companies, as the world struggled to find a cure for the disease and investors flocked to promising biotech companies working on COVID-19 vaccines. Famous biotech players like Moderna and Novavax Inc. soared to new highs as their vaccines started to show solid results. But relatively unknown biotech stocks like CytoDyn, Equillium Inc. and Humanigen Inc. also received a lot of attention as the world suddenly realized that its apparent progress in healthcare is not enough, and that we still have major existential problems to resolve.\nSmall Companies, Big IPOs\nJust after three years of inception, a biotech company named Sana Biotechnology recently went public, raising a whopping $58 million in what was reported to be the largest-ever IPO for a preclinical biotech. The Wall Street Journal reported before the IPO that the company, which makes technology for repairing and controlling genes in cells or replacing missing or damaged cells to treat several diseases, is valued at over $10 billion.\nBiotech companies burn a lot of cash and test investors’ patience before returning any money because they spend millions in research and development. But investors are ready to wait as they know the rewards are often big. After all, when Moderna went public in 2018, its $7 billion valuation looked insane and buying its stock felt risky. Today, the company is one of the fastest growing biotech companies in the US, and expects about $11.7 billion in revenue in 2021 just from the government-purchase agreements for its COVID-19 vaccine. Moderna shares have gained 472% over the last 12 months.\n NEstudio/Shutterstock.com \nAnother example is BioNTech, a once obscure German company that had to cut its IPO size after failing to satisfy investors. The company's shares soared to record highs after its vaccination (made in partnership with Pfizer) proved to be 90% effective. The stock is up 220% over the last 12 months. It's becoming harder for investors to spot stocks with solid and real value. Even the smart money is finding it difficult to keep track of the swiftly changing world. The hedge fund industry’s reputation has been tarnished in the last decade during which its hedged returns couldn’t keep up with the unhedged returns of the market indices. On the other hand, Insider Monkey’s strategy of focusing on the top picks of over 800 hedge funds has helped it consistently beat the market over the last several years. We launched our monthly newsletter’s activist strategy nearly 4 years ago and this strategy’s picks returned 187.5% since then and beat the SPY by 111 percentage points. Our short strategy was also launched 4 years ago and its short recommendations gained a cumulative 8% (that’s a good thing because we are shorting them) since then. You can improve your returns by subscribing to our premium newsletters. \nOur subscription prices start at $6.99 per month and come with a 14-day full refund guarantee. \nGrowth Potential for Biotech Stocks\nDeloitte in a January 2021 report said that the life sciences industry, which includes biotechnology, will be “stronger than ever” in 2021 amid a rising demand, artificial intelligence, increasing partnerships and scientific breakthroughs.\nDifference Between Biotech and Pharma\nThe biotech companies make use of living organisms for drug production but the pharmaceutical companies generally rely on chemicals and synthetic processes in order to manufacture medicines. Biotechnology brought a significantly new drug development strategy that did not fully amalgamate into the chemical-based approach of the established pharmaceutical companies.\nIn order to determine the fastest growing biotech companies in the US, we have compared the revenue of 2018 to the revenue of 2019 for some of the best and innovative biotech companies.\nLet's now take a look at our list of the 15 fastest growing biotech companies in the US.\n15. Sorrento Therapeutics, Inc. (NASDAQ: SRNE)\nHeadquarters: San Diego, CA\nNo. of employees: 310\nRevenue (2018): $21.2 million\nRevenue (2019): $31.43 million\nFounded in 2006, Sorrento Therapeutics, Inc. is a clinical-stage biotechnology company that makes novel immunotherapies for inflammatory, autoimmune, cancer, metabolic, and neurodegenerative maladies.  Its product portfolio incorporates biosimilars, cellular therapy, immuno-oncology antibodies, and antibody-drug conjugates (ADCs). The company's primary segment is related to Immune-Oncology therapeutic area while the Scilex segment is primarily concerned with the non-opioid pain management system.  Sorrento has established one of the most diverse antibody  libraries that boasts a myriad of superior quality, fully human antibodies.\nRegarding the COVID-19 pandemic, Sorrento is working on new antibody therapeutics. To develop an intramuscular injection that can neutralize Covid-19 and its variant strains, the company got a whopping $34 million contract from Defense Advanced Research Projects Agency (DARPA) in November.\nThe company has a slew of diagnostic tests and preventative/ treatment antibody treatments in its pipeline. Sorrento has already received clearance from FDA to proceed with Phase 1 Clinical Trials for STI-2020.\n14. Editas Medicine, Inc. (NASDAQ: EDIT)\nHeadquarters: Cambridge, Massachusetts\nNo. of employees: 208\nRevenue (2018): $32 million\nRevenue (2019): $20.5 million\nFounded in 2013, Editas Medicine, Inc. is a genome editing company that makes therapies based on CRISPR genome editing systems. The CRISPR technology entails CRISPR/Cas9, CRISPR/Cas12a, and the engineered hybrid of these two systems to target the diseases at the genetic level. It is also involved in research collaboration with Juno Therapeutics, Inc.\n13. Intellia Therapeutics, Inc. (NASDAQ: NTLA)\nHeadquarters: Cambridge, Massachusetts\nNo. of employees: 270\nRevenue (2018): $30.4 million\nRevenue (2019): $43.1 million\nFounded in 2014, Intellia Therapeutics is a biotechnology company that is a pioneer in the development of CRISPR/Cas9 genome editing.  The company uses Lipid Nanoparticle (LNP) for the delivery of the CRISPR/Cas9 complex to the liver. It has a license agreement and strategic collaboration with Novartis on developing novel ex vivo CRISPR/Cas9-based therapies. The company's NTLA-2002 is a candidate for the treatment of Hereditary Angioedema (HAE) while NTLA-5001 is their initial ex vivo development candidate which targets to treat Acute Myeloid Leukemia (AML).\nThe new division of the company, eXtellia Therapeutics, is engaged in the application of CRISPR/Cas9 genome editing in the domain of immuno-oncology and autoimmune/inflammatory diseases.\n12. Blueprint Medicines Corporation (NASDAQ: BPMC)\nHeadquarters: Cambridge, Massachusetts\nNo. of employees: 420\nRevenue (2018): $44.5 million\nRevenue (2019): $66.5 million\nFounded in 2008, Blueprint Medicines Corporation is a biopharmaceutical company that focuses on the diseases triggered by kinase activation. In January 2020 BLU-285(Ayvakit) was approved by the FDA as a treatment of metastatic GIST harboring a PDGFRA exon 18 mutation as well as PDGFRA D842V mutations. Its drug BLU-667(Gavreto) won the FDA approval for the treatment of adults with metastatic RET fusion-positive non-small-cell lung cancer (“NSCLC”). The company's pipeline of primary drug candidates includes BLU-554(Fisogatinib), which is for patients with advanced Hepatocellular Carcinoma (HCC), and BLU-945, which is designed to target EGFR tumors.\n11. Acceleron Pharma Inc. (NASDAQ: XLRN)\nHeadquarters: Cambridge, Massachusetts.\nNo. of employees: 237\nRevenue (2018): $14 million\nRevenue (2019): $74 million\nFounded in 2003, Acceleron Pharma Inc. is a biopharmaceutical company that is involved in developing protein therapies to neutralize certain types of rare diseases and cancer.  The company has prioritized and focused its research and development projects around three main therapeutic fields: neuromuscular, pulmonary, and hematology.\nOn April 3, 2020, the FDA approved the company's luspatercept-aamt for anemia in adults with MDS. Its candidates which are undergoing clinical trials include ACE-083, designed for the treatment of focal muscle disorders; Sotatercept, designed to treat pulmonary arterial hypertension; and ACE-1334 for the treatment of Systemic Sclerosis.\nThe company has partnerships with biotech giants like Bristol-Myers Squibb, Alkermes and Shire.\n10. Fate Therapeutics, Inc. (NASDAQ: FATE)\nHeadquarters: San Diego, California\nNo. of employees: 178\nRevenue (2018): 4.740 million\nRevenue (2019): 10.7 million\nRanking 10th on our list of 15 fastest growing biotech companies in the US is Fate. Founded in 2007, Fate Therapeutics, Inc. is a biopharmaceutical company that is engaged in the development of programmed cellular immunotherapies for immune disorder and cancer.  Its pipeline of products entails immuno-regulation candidates and immuno-oncology candidates. ProHema is its lead candidate drug which utilizes the blood of the umbilical cord to treat hematologic malignancies. The company programs immune cells, such as T cells, Natural Killer (NK) cells, and CD34+ cells by utilizing its cell programming approach. Its under-development programs include FT500, FT516, and FT-ONO2 to treat advanced solid tumors; FT516 to treat acute myeloid leukemia (AML) and B-cell lymphoma; FT538 for the treatment of AML and multiple myeloma; FT576 to treat multiple myeloma; FT596 to treat B-cell lymphoma and CLL; FT819 to treat B-cell malignancies, and FT-ONO1 to treat hematologic malignancies.\n9. Mirati Therapeutics, Inc. (NASDAQ: MRTX)\nHeadquarters: San Diego, California\nNo. of employees: 111\nRevenue (2018): $13 million\nRevenue (2019): $3.3 million\nFounded in 1995, Mirati Therapeutics, Inc. ranks 9th on our list of 15 fastest growing biotech companies in the US. It has a pipeline of oncology products for treating particular genetic and epigenetic drivers of cancer in selected subsets of patients having limited treatment options.  The company's clinical programs include two major product candidates: Sitravatinib, a multi-kinase inhibitor, and MRTX849, a Kirsten Rat Sarcoma (KRAS) G12C inhibitor. MRTX849 is designed for treating non-small cell lung (NSCL), pancreatic, colorectal, and other cancers while Sitravatinib is designed for treating NSCL cancer, and for inhibiting receptor tyrosine kinases (RTKs).\n8. Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)\nHeadquarters: Novato, California.\nNo. of employees: 740\nRevenue (2018): $51.5 million\nRevenue (2019): $104 million\nFounded in 2010, Ultragenyx Pharmaceutical Inc., is one of the 15 fastest growing biotech companies in the US. It works on novel drugs for neutralizing rare and ultra-rare diseases concerned with genetics. The candidate products of Ultragenyx are categorized into three types: gene therapy, biologics, and small molecule products. The portfolio of the company's medicine includes Crysvita (KRN23), Mepsevii (UX003), and Triheptatonin (UX007). Crysvita is for treating the X-linked hypophosphatemia (XLH) in adults and pediatric patients while Mepsevii is for treating the Mucopolysaccharidosis VII indicated in pediatric and adult patients. The US market accounts for around 85% of the company's revenue.\nThe company's clinical-stage pipeline consists of two candidates: DTX 301 which is developed for the treatment of individuals with ornithine transcarbamylase (OTC) deficiency and DTX 401 for the treatment of patients with Glycogen Storage Disease Type 1a (GSDIa).\n7. AbCellera Biologics Inc. (NASDAQ: ABCL)\nHeadquarters: Vancouver, Canada.\nNo. of employees:  174\nRevenue (2018): $8.8 million\nRevenue (2019): $11.6 million\nFounded in 2012, AbCellera Biologics Inc. is a biotechnology company that focuses on developing antibodies to prevent and treat highly infectious diseases.  Its platform entails and integrates technology tools from single- microfluidics, cell analysis, engineering, high-throughput genomics, data science, and machine learning.  The company is also involved in developing next-generation transgenic mice for the detection of therapeutic antibody candidates.\nThe company's subsidiaries include AbCellera Properties Columbia Inc., AbCellera Properties Inc., Lineage Biosciences Inc., Channel Biologics Pty Ltd., AbCellera US Holdings Inc. and Trianni, Inc.\nBamlanivimab (LY-CoV555), the drug discovered by AbCellera and developed with Eli Lily & Co., has received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) to be used in combination with Etesevimab (LY-CoV016) for the treatment of COVID-19.\n6. Zai Lab Limited (NASDAQ: ZLAB)\nHeadquarters: Shanghai, China.\nNo. of employees: 859\nRevenue (2018): $129,000\nRevenue (2019): $12.9 million\nRanking 6th on our list of 15 fastest growing biotech companies in the US is ZLAB. Zai Lab Limited is a biopharmaceutical company that focuses on developing and commercializing drugs related to the fields of oncology, autoimmune, and infectious diseases. The flagship products of the company include Niraparib for the treatment of multiple solid tumors, and Optune, a cancer therapy for treating glioblastoma multiforme. The company's pipeline of proprietary drug candidates includes discovery-stage to late-stage clinical programs. It includes Fugan (ZL-3101), ZL-2103, ZL-2302, ZL-1101, and several others.\nClick to continue reading and see 5 Fastest Growing Biotech Companies in the US.\nSuggested articles:\n\n15 Fastest Growing Channels On YouTube in 2020\n15 Biggest Outsourcing Companies In The World\n10 Best Long-Term Dividend Stocks to Buy and Hold\n\nDisclosure: None. 15 Fastest Growing Biotech Companies in the US is originally published on Insider Monkey.","news_type":1,"symbols_score_info":{"ABCL":0.6,"BNTX":0.6,"BPMC":0.6,"CVAC":0.6,"EDIT":0.6,"FATE":0.6,"MRNA":0.6,"MRTX":0.9,"NTLA":0.6,"NVAX":0.6,"RARE":0.6,"SGEN":0.6,"SRNE":0.6,"TERN":0.9,"XLRN":0.6,"ZLAB":0.6}},"isVote":1,"tweetType":1,"viewCount":2200,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}